In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Intellia Therapeutics Inc. Trade Record

NASDAQ:NTLA Intellia Therapeutics Inc stock gains 5.14% Exit Aug 1, 2019 a Trade Record by priceseries

Trade Chart
Trade Chart NTLA Jul 17, 2019, priceSeries
About Intellia Therapeutics Inc

Intellia Therapeutics Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism; and ex vivo applications of the technology in chimeric antigen receptor T cell and hematopoietic stem cell product candidates. It has a strategic collaboration and license agreement with Novartis focused on the development of new ex vivo CRISPR/Cas9-based therapies. Intellia Therapeutics Inc. was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics Inc. in July 2014. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Trade Information
Trade Type
LONG
ReliabilityScore™
94.12
Entry Date
Jul 17, 2019
Entry Price
16.69
Sell Date
Aug 1, 2019
Sell Price
17.55
Net Gain
5.14%
Hold Time
11 Trading Days